Company: IMRX
Filing Date: 2025-01-07
Form Type: 8-K
Source: 0001790340-25-000012
Chunk: 3

Company: Immuneering Corp
Filing Date: 2025-01-07
Form: 8-K
Item: Item 8.01
Chunk 3
---
, plans for additional IMM-1-104 combination therapy trials, and the timing of release of additional data from the ongoing Phase 1/2a clinical trial of IMM-1-104.

These forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials.

These and other important factors discussed under the caption “ Risk Factors” in our Quarterly Report on Form 10-Q for the three month period ended September 30, 2024 and filed with the U. S. Securities and Exchange Commission (the “ SEC”) on November 13, 2024 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management’s estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                             IMMUNEERING CORPORATION                                                
  Date: January 7, 2025      By:                          /s/ Michael D. Bookman                    
                                                          Name: Michael D. Bookman                  
                                                          Title: Chief Legal Officer and Secretary